The allogeneic bone marrow-derived mesenchymal stromal cell (MSC) therapy Ryoncil (remestemcel-L-rknd) has been approved for ...

A seismic shift in pediatric medical care has arrived with the FDA’s approval of Ryoncil (remestemcel-L-rknd), a ...

While gene therapy has emerged as a promising alternative for treating beta-thalassemia, hematopoietic stem cell ...

The Food and Drug Administration (FDA) has approved Ryoncil ® (remestemcel-L-rknd) for the treatment of steroid-refractory acute graft vs host disease (SR-aGvHD) in pediatric patients 2 months of age ...

“It is clear that NETs contribute to DED and this licensing agreement represents an important step in bringing our innovative treatments to patients who live with the daily challenges of DED,” said ...

New imaging technique able to identify early signs of graft-versus-host-disease in transplant patients. Read on!

Incyte (NASDAQ:INCY – Get Free Report) had its price objective boosted by analysts at Wells Fargo & Company from $68.00 to ...

The Advanced Research Projects Agency for Health (ARPA-H) awarded TigaTx up to $33.5 million in funding. Tessera Therapeutics ...

Meanwhile, synthetic gel aids in recovery after spinal surgery; Pittsburgh researchers create helper robots for people with ALS; a study finds nerve stimulation is effective against ...

Mesoblast Limited MESO announced that the FDA has approved Ryoncil (remestemcel-L) for the treatment of steroid-refractory ...

Reaching the end of a long road to approval, the first mesenchymal stromal cell (MSC) therapy for steroid-refractory acute ...

More than four years later—and after two rejections from the agency—Mesoblast has finally gained an endorsement from the U.S.